Compound ID	CDAMM01611
Common name	Dolichantoside
IUPAC name	methyl 3-ethenyl-4-[(2-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl)methyl]-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-5-carboxylate
Molecular formula	C₂₈H₃₆N₂O₉

Experimental data

Retention time	3.6
Adduct	[M+H]+
Actual mz	545.252
Theoretical mz	545.249
Error	5.73
Ionizaton mode	Positive
Instrument type	LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score	7.2825

Identifiers and class information

Inchi key	SLMISZLSXLAAKK-OFHSULMRNA-N
Smiles	O=C(OC)C1=COC(OC2OC(CO)C(O)C(O)C2O)C(C=C)C1CC3C=4NC=5C=CC=CC5C4CCN3C
Superclass	Lipids and lipid-like molecules
Class	Prenol lipids

Plant source

Cinnamomum tamala (Buch.-Ham.) T.Nees & C.H.Eberm.

External sources

HMDB ID
KNApSAcK ID	C00028215
FooDB ID
DrugBank ID
ChEBI ID
Pubchem Compound ID	73803915
PlantCyc ID
UNPD ID	UNPD127610
Coconut ID	CNP0207090
LipidMAPS ID
NANPDB ID

Pharmacokinetic properties

Number of descriptor values(#stars)	1
Number of non-conjugated amine groups (#amine)	1
Number of amidine and guanidine groups (#amidine)	0
Number of carboxylic acid groups (#acid)	0
Number of non-conjugated amide groups (#amide)	0
Number of rotatable bonds (#rotor)	11
Number of reactive functional groups (#rtvFG)	3
Predicted central nervous system activity (CNS)	-2
Molecular weight (mol_MW)	544.6
Computed dipole moment(dipole)	7.701
Total solvent accessible surface area (SASA)	852.828
Hydrophobic component of SASA (FOSA)	447.664
Hydrophilic component of SASA (FISA)	201.145
Pie component of the SASA (PISA)	204.019
Weakly polar component of the SASA (WPSA)	0
Total solvent accesible volume (volume)	1613.57
Number of hydrogen bond donors (donorHB)	5
Number of hydrogen bond acceptors (accptHB)	15.9
Free energy of solvation of dipole (dip^2/V)	0.036757
Index of cohesive interaction in solids (ACxDN^.5/SA)	0.0416889
Globularity descriptor (glob)	0.780123
Predicted polarizability in cubic angstroms (QPpolrz)	53.307
Predicted hexadecane/gas partition coefficient (QPlogPC16)	17.305
Predicted octanol/gas partition coefficient (QPlogPoct)	34.217
Predicted water/gas partition coefficient (QPlogPw)	25.085
Predicted octanol/water partition coefficient (QPlogPo/w)	0.748
Predicted aqueous solubility (QPlogS)	-3.202
Conformation-independent predicted aqueous solubility (CIQPlogS)	-3.573
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)	-6.789
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)	30.573
Predicted brain/blood partition coefficient (QPlogBB)	-1.904
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)	12.62
Predicted skin permeability, log Kp (QPlogKp)	-5.514
PM3 calculated ionization potential (IP(ev))	7.911
PM3 calculated electron affinity (EA(eV))	0.179
Number of likely metabolic reactions (#metab)	10
Prediction of binding to human serum albumin (QPlogKhsa)	-0.534
Predicted qualitative human oral absorption (HumanOralAbsorption)	1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)	31.995
Solvent-accessible surface area of fluorine atoms (SAFluorine)	0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)	0
Van der Waals surface area (PSA)	157.369
Number of nitrogen and oxygen atoms (#NandO)	11
Number of violations of Lipinskiâ€™s rule of five (RuleOfFive)	2
Number of violations of Jorgensenâ€™s rule of three (RuleOfThree)	1

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID	Gene name	Target name	TTD_ID	Prediction source
P18825	ADRA2C	Adrenergic receptor alpha-2	T01777	SEA
P11387	TOP1	DNA topoisomerase I	T09826	SEA
P15692	VEGFA	Vascular endothelial growth factor A	T20761	SEA
P05230	FGF1	Acidic fibroblast growth factor	T18639	SEA
P09038	FGF2	Basic fibroblast growth factor	T31621	SEA
P60568	IL2	Interleukin-2	T61698	SEA
P17931	LGALS3	Galectin-3	T72038	SEA
P04746	AMY2A	Pancreatic alpha-amylase	T86918	SEA

Target associated diseases

TTD_ID	Disease_ID	Disease name	ICD_11	Uniprot ID	Gene names
T01777	DI0166	Glaucoma	[ICD-11: 9C61]	P18825	ADRA2C
T01777	DI0190	Hypertension	[ICD-11: BA00-BA04]	P18825	ADRA2C
T01777	DI0196	Hypotension	[ICD-11: BA20-BA21]	P18825	ADRA2C
T01777	DI0308	Obesity	[ICD-11: 5B80-5B81]	P18825	ADRA2C
T01777	DI0310	Ocular disease	[ICD-11: N.A.]	P18825	ADRA2C
T01777	DI0396	Substance abuse	[ICD-11: 6C40]	P18825	ADRA2C
T09826	DI0046	Bacterial infection	[ICD-11: 1A00-1C4Z]	P11387	TOP1
T09826	DI0095	Colorectal cancer	[ICD-11: 2B91]	P11387	TOP1
T09826	DI0238	Lung cancer	[ICD-11: 2C25]	P11387	TOP1
T09826	DI0321	Ovarian cancer	[ICD-11: 2C73]	P11387	TOP1
T09826	DI0391	Solid tumour/cancer	[ICD-11: 2A00-2F9Z]	P11387	TOP1
T20761	DI0095	Colorectal cancer	[ICD-11: 2B91]	P15692	VEGFA
T20761	DI0365	Retinopathy	[ICD-11: 9B71]	P15692	VEGFA
T20761	DI0430	Vascular system developmental anomaly	[ICD-11: LA90]	P15692	VEGFA
T18639	DI0081	Chronic arterial occlusive disease	[ICD-11: BD4Z]	P05230	FGF1
T18639	DI0102	Coronary atherosclerosis	[ICD-11: BA52]	P05230	FGF1
T31621	DI0005	Acne vulgaris	[ICD-11: ED80]	P09038	FGF2
T61698	DI0275	Multiple sclerosis	[ICD-11: 8A40]	P60568	IL2
T61698	DI0361	Renal cell carcinoma	[ICD-11: 2C90]	P60568	IL2
T72038	DI0190	Hypertension	[ICD-11: BA00-BA04]	P17931	LGALS3
T72038	DI0199	Idiopathic interstitial pneumonitis	[ICD-11: CB03]	P17931	LGALS3
T72038	DI0252	Melanoma	[ICD-11: 2C30]	P17931	LGALS3
T72038	DI0302	Non-alcoholic fatty liver disease	[ICD-11: DB92]	P17931	LGALS3
T72038	DI0351	Psoriasis	[ICD-11: EA90]	P17931	LGALS3
T86918	DI0110	Cystic fibrosis	[ICD-11: CA25]	P04746	AMY2A
T86918	DI0328	Pancreatic malfunction	[ICD-11: DC30-DC3Z]	P04746	AMY2A